Core Insights - Yuyue Medical's stock price on August 22 was 36.60 yuan, down 0.25% from the previous trading day, with a trading volume of 4.17 billion yuan [1] - The company reported a 2025 semi-annual revenue of 4.659 billion yuan, an increase of 8.16% year-on-year, and a net profit attributable to shareholders of 1.203 billion yuan, up 7.37% year-on-year [1] - The company announced a mid-term dividend plan, proposing a cash dividend of 2 yuan for every 10 shares [1] Business Performance - The blood glucose management and POCT solutions segment experienced significant growth, with revenue increasing by 20% year-on-year [1] - The emergency solutions and other segments saw a revenue increase of 30.54% year-on-year [1] Capital Flow - On August 22, Yuyue Medical experienced a net outflow of 15.1716 million yuan in main funds, while the net inflow over the past five days was 1.24 billion yuan [1]

证券日报网讯 8月22日晚间，鱼跃医疗发布关于公司2025年半年度利润分配方案的公告称，公司拟向全 体股东每10股派发现金红利2.00元（含税）。按照目前公司总股本1，002，476，929股为基数进行计 算，预计本次派发现金红利总额为200，495，385.80元。 （编辑 任世碧） ...

Core Viewpoint - The CSI All Share Healthcare Equipment and Services Index has shown significant growth, reflecting a positive trend in the healthcare sector, with a notable increase in trading volume and index performance over various time frames [1][2]. Group 1: Index Performance - The CSI All Share Healthcare Equipment and Services Index rose by 0.14% to 15,554.17 points, with a trading volume of 35.351 billion [1]. - Over the past month, the index has increased by 10.85%, by 14.71% over the last three months, and by 13.47% year-to-date [1]. Group 2: Index Composition - The index comprises companies related to the healthcare theme, with the top ten weighted companies being Mindray Medical (9.17%), United Imaging (7.63%), Aier Eye Hospital (7.12%), and others [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (59.89%) and the Shanghai Stock Exchange (40.11%) [1]. Group 3: Industry Representation - The index exclusively represents the healthcare sector, with a 100% allocation to pharmaceutical and healthcare-related companies [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. Group 4: Investment Products - Several public funds track the CSI All Share Healthcare Equipment and Services Index, including various Southern and Tianhong funds, as well as ETFs from different asset management companies [2].

Core Insights - Yuyue Medical reported a revenue of 4.659 billion yuan for the first half of 2025, representing a year-on-year growth of 8.16%, and a net profit attributable to shareholders of 1.203 billion yuan, up 7.37% year-on-year [1] - The company is focusing on technological innovation, applying AI and other advanced technologies in product development and operational management, while building a comprehensive product ecosystem centered on digitalization and wearability [1][3] - Yuyue Medical is committed to expanding its global presence, enhancing overseas channel construction, and nurturing international talent to tap into the vast potential of the global market [1] Business Performance - The respiratory therapy solutions generated revenue of 1.674 billion yuan, a year-on-year increase of 1.93%, while blood glucose management and POCT solutions achieved revenue of 674 million yuan, growing by 20.00% [2] - Emergency solutions and other segments reported revenue of 136 million yuan, up 30.54%, and home health testing solutions reached 1.014 billion yuan, increasing by 15.22% [2] - Clinical instruments and rehabilitation solutions generated revenue of 1.134 billion yuan, reflecting a growth of 3.32%, showcasing the company's strong position in the home medical device sector [2] R&D and Innovation - Yuyue Medical invested 295 million yuan in R&D during the first half of 2025, marking a 9.44% increase year-on-year, with total R&D investment exceeding 2.4 billion yuan over the past five years [2] - The company has launched several new products, including the Anytime5 glucose monitoring system and portable AEDs, while accelerating the IoT integration of its products to provide comprehensive health management solutions [2][4] Global Strategy - The company achieved overseas revenue of 607 million yuan, a year-on-year growth of 26.63%, and obtained 85 international registrations to support global product promotion [3] - Yuyue Medical is enhancing its overseas team and local sales network to ensure the successful establishment and growth of its international business [3] Ecosystem Development - Yuyue Medical is building an integrated health management ecosystem that combines hardware, software, and data, launching the Yuyue AI Agent health management application to enhance user engagement and data management [4] - The company emphasizes the development of AI-enabled wearable medical devices for continuous monitoring of health indicators such as blood glucose and blood pressure [3][4] Future Outlook - The chairman of Yuyue Medical stated the company's commitment to long-termism, global vision, and strategic calibration, with a focus on AI as a lever for deepening globalization, digitalization, and wearability strategies [4]

Core Insights - Yuyue Medical reported a revenue of 4.659 billion yuan for the first half of 2025, representing a year-on-year growth of 8.16%, and a net profit attributable to shareholders of 1.203 billion yuan, up 7.37% year-on-year [1] - The company is focusing on three strategic directions: globalization, digitalization, and wearability, aiming to establish a solid foundation for long-term development [1] Business Performance - The respiratory therapy solutions generated revenue of 1.674 billion yuan, a year-on-year increase of 1.93% [2] - Blood glucose management and POCT solutions achieved revenue of 674 million yuan, growing by 20.00% [2] - Emergency solutions and other segments reported revenue of 136 million yuan, up 30.54% [2] - Home health monitoring solutions earned 1.014 billion yuan, with a growth of 15.22% [2] - Clinical instruments and rehabilitation solutions generated revenue of 1.134 billion yuan, increasing by 3.32% [2] - The company maintains its leadership in the home medical device sector with steady growth across diverse business segments [2] Technological Advancements - Yuyue Medical has made significant progress in AI healthcare, integrating artificial intelligence, big data, and IoT into its operations and product development [2] - The company is focusing on developing AI-enabled wearable medical devices that monitor blood glucose, blood pressure, and blood oxygen levels [2] Future Outlook - The chairman of Yuyue Medical emphasized a commitment to long-termism, a global perspective, and leveraging AI to deepen the company's strategies in globalization, digitalization, and wearability [3]

资料显示，鱼跃医疗成立于1998年，位于江苏省丹阳市开发区百胜路1号，是一家以从事提供家用医疗 器械、医用临床产品以及与之相关的医疗服务为主的企业。企业注册资本10.02亿人民币，法人代表为 吴群。 来源：金融界 鱼跃医疗半年报数据显示，2025年1-6月营业总收入为46.59亿元，较去年同期增长8.16%，净利润为 12.03亿，较去年同期增长7.37%，每股收益1.2049元，净资产收益率为9.21%，每股经营现金流量为 1.1640元，销售毛利率为50.37%，所处行业为医疗器械。 通过天眼查大数据分析，江苏鱼跃医疗设备股份有限公司共对外投资了36家企业，参与招投标项目2166 次；知识产权方面有商标信息719条，专利信息1016条；此外企业还拥有行政许可2294个。 ...

鱼跃医疗8月22日晚间发布公告称，公司第六届第五次董事会会议于2025年8月22日以通讯表决的方式召 开。会议审议了《公司2025年半年度报告及其摘要》等文件。 （文章来源：每日经济新闻） ...

格隆汇8月22日丨鱼跃医疗(002223.SZ)公布2025年半年度报告，上半年公司实现营业收入46.59亿元，同 比增长8.16%；归属于上市公司股东的净利润12.03亿元，同比增长7.37%；归属于上市公司股东的扣除 非经常性损益的净利润9.14亿元，同比下降5.22%；基本每股收益1.2049元；拟向全体股东每10股派发 现金红利2元(含税)。 ...

江苏鱼跃医疗设备股份有限公司 2025 年上半年度 财务报告 （未经审计） 资产负债表 | 编制单位:江苏鱼跃医疗设备股份有限公司 | 2025 | 年 6 月 30 日 | | 单位:人民币元 | | --- | --- | --- | --- | --- | | 资 产 | 期末余额 | | 期初余额 | | | | 合并数 | 母公司 | 合并数 | 母公司 | | 流动资产： | | | | | | 货币资金 | 7,230,481,000.15 | 6,559,853,482.27 | 6,618,648,637.69 | 6,134,712,052.65 | | 结算备付金 | | | | | | 拆出资金 | | | | | | 交易性金融资产 | | | | | | 衍生金融资产 | | | | | | 应收票据 | 12,063,446.19 | 6,600,467.24 | 26,877,764.76 | 22,399,504.25 | | 应收账款 | 1,184,722,827.85 | 825,331,349.57 | 715,146,307.99 | 587,531,287.27 ...

江苏鱼跃医疗设备股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用 | 占用方与 上市公司 | 上市公司核 | 2025 年期初 | 2025 年 1-6 月占用累计 | 2025年1-6 月占用资 | 2025 年 1-6 | 2025 年 6 月 | 占用形成 | | | 非经营性资金占用 | 方名称 | 的关联关 | 算的会计科 | 占用资金余 | 发生金额 | 金的利息 | 月偿还累计 | 30 日占用资 | 原因 | 占用性质 | | | | | 目 | 额 | （不含利 | | 发生金额 | 金余额 | | | | | | 系 | | | | （如有） | | | | | | | | | | | 息） | | | | | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小 ...